Aug 2026· Chemical Biology and Drug Design· Vol 108· 0 citations· 58 references
Medicine
TL;DR
This review uniquely addresses that gap by presenting an integrated framework that connects molecular design principles with clinical applicability in gRNAs by presenting an integrated framework that connects molecular design principles with clinical applicability.
Abstract
CRISPR–Cas9 has revolutionised genome editing by enabling efficient and programmable modification of defined DNA sequences, with guide RNAs (gRNAs) serving as indispensable elements that direct Cas9 to specific genomic loci. Initially regarded as auxiliary components, gRNAs are now recognized as critical determinants of editing efficiency and specificity and have attracted growing attention as independent targets for engineering. Chemical modification, sequence optimisation, and structural alteration of gRNAs have been shown to enhance on‐target activity, suppress off‐target effects and cytotoxicity, and even achieve allele‐selective precision editing in a programmable manner. Moreover, advances in artificial intelligence and machine learning have markedly improved the predictive accuracy of gRNA design through large‐scale data analysis. Despite rapid progress, a consolidated review that integrates chemical, structural, and computational advances in gRNA engineering and highlights their translational potential for therapeutic genome editing has been lacking. This review uniquely addresses that gap by presenting an integrated framework that connects molecular design principles with clinical applicability.
Genomic manipulation has advanced from stochastic nuclease‐mediated disruption toward programmable, deterministic precision. Early clustered regularly interspaced short palindromic repeats (CRISPR) strategies enabled targeted mutagenesis through double‐strand breaks; however, their therapeutic application is limited by genotoxicity, chromosomal instability, and dependence on endogenous repair pathways that are difficult to predict. In this review, we examined the transition from gene editing to genome writing, an approach that decouples genomic modification from host repair pathways to better balance efficiency, precision, and payload delivery. We also discussed the principles of precision technologies, including base and prime editors, and described emerging large‐scale writers, such as CRISPR‐associated transposases and recombinase‐based bridge RNAs, which enable the integration of multi‐kilobase synthetic modules. Beyond enzymatic mechanisms, we further considered the combined use of generative artificial intelligence, structural biology, and novel delivery architectures as potential strategies to overcome current biological limitations. Taken together, these developments point toward Generative Biology, in which computational design and high‐throughput screening transform the genome from a static substrate into a more dynamic model for complex, synthetic functional design.
The current developments in engineering of Cas effector protein, optimizing guide RNA designs, developing advanced reporter probes, and utilizing chemical additives are summarized and their significant contribution to increasing the fidelity of editing and diagnostic sensitivity is highlighted.
Sheng Li, Han Li, Bojie Chen et al.· Interdisciplinary Medicine· 1 citation
CRISPR has emerged as a next-generation gene-editing tool with the potential to target the molecular pathways associated with ageing and related disorders. It functions through RNA-guided Cas nucleases, directing DNA cleavage and utilizing the native DNA repair machinery for genetic manipulations. Advances in CRISPR technology have significantly enhanced the precision and flexibility of techniques for genome editing. The enzyme Cas9's ability to cut DNA at exact site has revolutionized genome editing by enabling accurate modifications within living eukaryotic cells. This review critically examines recent developments in CRISPR-based technologies, including Cas9, Cas12, base editing, prime editing, and CRISPR-mediated gene regulation. It highlights their rising applications in ageing research, with more emphasis on neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. The review also discusses the major pharmacological and translational challenges that currently limit clinical applications, including inefficient tissue-specific delivery, off-target genome editing, immunogenicity, manufacturing complexity, and long-term safety concerns. Also, recent progress in both, viral and non-viral delivery methods are critically evaluated, including adeno-associated viruses, lentivirus vectors, lipid nanoparticles, gold nanoparticles, exosomes, electroporation, and microinjection, is thoroughly discussed to highlight their therapeutic potential and translational limitations. Current studies indicate that CRISPR-based approaches have preclinical potential for targeting important hallmarks of ageing, particularly genomic instability, telomere attrition, and mitochondrial dysfunction. Other hallmarks of ageing, such as stem cell exhaustion, epigenetic modifications, and microbiome changes, are at earlier stages of development. Overall, this review describes future strategies for developing safe, precise, and clinically translatable CRISPR-based treatments to promote healthy ageing.
Sakshi Rathore, Akash Gupta, Kamal Shah et al.· Ageing Research Reviews· 0 citations
The convergence of CRISPR-Cas9 genome editing and nanozyme engineering is revolutionizing synthetic biology, biotechnology, and medical science. CRISPR-Cas9, a precise and programmable tool, enables targeted genetic modifications that enhance nanozyme functionality, stability, and catalytic efficiency. Through the site-specific mutagenesis, metabolic pathway regulation, and synthetic biology strategies, researchers have significantly improved nanozyme performance for diverse applications, including environmental remediation, biomedical diagnostics, and industrial catalysis. This article explores the fundamental mechanisms of CRISPR-based genome editing, its role in nanozyme optimization, and the latest breakthroughs in enzyme engineering. It also critically examines challenges such as off-target effects, biosafety concerns, and ethical implications associated with gene-edited nanozymes. As advancements in AI-driven predictive modeling and next-generation gene-editing tools emerge, CRISPR-Cas9 is poised to unlock unprecedented possibilities in bioengineering. The integration of genetic precision with catalytic innovation marks a transformative era, redefining the frontiers of molecular biotechnology and paving the way for groundbreaking applications in medicine, industry, and sustainable technology.
Modamori I.O, Okanlawon T.S, Ebhomienlen J.O et al.· Biological and Environmental...· 0 citations
CRISPR-Cas9 has transformed gene editing; however, it is based on doublestrand
DNA breaks, which may result in unintentional mutations and structural alterations,
thereby limiting its clinical translation. Instead of DSBs, new precision instruments,
including prime editing, can be used to perform accurate search-and-replace DNA editing
with a Cas9 nickase and reverse transcriptase. Prime editing can perform all base substitutions
and small edits with improved precision and reduced off-target activity, which has
promising results in disease modelling with patient-derived organoids. Nonetheless, it is
cumbersome, inefficient, and thus hard to deliver. This is improved by the Programmable
Addition via Site-specific Targeting Elements system, which uses Prime editing in combination
with serine integrases to insert large DNA sequences with no gaps to provide
lasting gene replacement and maintain natural gene regulation. Emerging delivery options,
including lipid nanoparticles, dual adeno-associated virus systems, and virus-like
particles, allow the delivery to be transient and tissue-targeted, which minimizes the risks
over the long-term. Early clinical translation efforts are currently underway, with the first
FDA-approved trial of one Prime editing-based therapy, but it has been struggling with
efficiency, safety, and delivery. Future success will depend on predictive machinelearning
devices and strictly controlled editing systems. Genome engineering is evolving
from a DNA-cutting system to a precise and programmable genome editing system,
which may support the future development of safer and more precise therapeutic strategies.
Vikash Kumar, Aman Kumar, Balak Das Kurmi· Current Pharmacogenomics and...· 0 citations
Natural variation in PAM recognition among SaCas9 orthologs is analyzed and StaCas9 is identified as a compact and efficient nuclease recognizing an NNG PAM, establishing StaCas9 as a high-performance genome-editing tool for therapeutic applications.
